natgillin/translations-raw huggingface dataset:
The pharmaceutical composition of claim 9, further comprising an additional therapeutic agent; optionally, wherein the additional therapeutic agent is selected from the group consisting of human immunodeficiency virus (HIV) protease inhibiting compounds, HIV nonnucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, and CCR5 inhibitors. 
Farmaceutski sastav prema patentnom zahtjevu 9, koji nadalje, sadrži dodatni terapijski agens; opcionalno, gdje je dodatni terapijski agens izabran iz grupe koja se sastoji od spojeva inhibitora proteaze virusa humane imunodeficijencije (HIV), nenukleozidnih inhibitora HIV reverzne transkriptaze, nukleozidnih inhibitora HIV reverzne transkriptaze, nukleotidnih inhibitora HIV reverzne transkriptaze, inhibitora HIV integraze i CCR5 inhibitora.
A method for preparing tenofovir alafenamide hemifumarate comprising subjecting a solution comprising: a) a suitable solvent; b) fumaric acid; c) tenofovir alafenamide; and d) one or more seeds of tenofovir alafenamide hemifumarate, to conditions that provide for the crystallization of the fumaric acid and the tenofovir alafenamide; optionally, wherein the solvent comprises acetonitrile; and/or, wherein the solution is subjected to a temperature in the range of from about 0 °C to about 75 °C. 
Metoda za pripremu tenofovir alafenamid hemifumarata koja uključuje podvrgavanje rastvora, koji sadrži: a) odgovarajuće otapalo; b) fumarinsku kiselinu; c) tenofovir alafenamid; i d) jedno ili više zrna tenofovir alafenamid hemifumarata, uvjetima koji uzrokuju kristalizaciju fumarinske kiseline i tenofovir alafenamida; opcionalno, gdje otapalo sadrži acetonitril; i/ili otopina je podvrgnuta temperaturama u rasponu od oko 0°C do oko 75°C.
The connector of claim 2 wherein the tap portion (28) is disposed perpendicular to the two swage regions (24) in a tee configuration. 
Priključak prema zahtjevu 2 naznačen time da je dio slavine (28) postavljen okomito na dva uprešana područja (24) u T konfiguraciji.
compressing the swage regions (24) radially inwardly with a swaging tool. 
komprimiranje uprešanih područja (24) radijalno prema unutra s alatom za uprešavanje.
Process for packing products based on portions of fish in the solid form, characterized in that it comprises at least: 
Postupak pakiranja proizvoda koji se temelje na porcijama ribe u čvrstom obliku, naznačen time što obuhvaća barem:
the step of introducing (120) one or more portions of raw fish in the solid form in the frozen state into an at least partially flexible packaging; 
korak uvođenja (120) jedne ili više porcija sirove ribe u čvrstom obliku u smrznutom stanju u barem djelomice fleksibilno pakiranje;
the step of performing mechanical vacuum (130) inside said packaging filled in with said one or more portions of fish in the solid form in the frozen state; 
korak izvođenja mehaničkog vakuuma (130) unutar pakiranja ispunjenog jednom ili više porcija ribe u čvrstom obliku u smrznutom stanju;
the step of sealing (140) said packaging so as to form a sealed package comprising said one or more portions of fish in the solid form still in the frozen state; 
korak zatvaranja (140) pakiranja na način da tvori zatvoreno pakiranje koje obuhvaća jednu ili više porcija ribe u čvrstom obliku u smrznutom stanju;
Process according to claim 1, characterized in that said sealed packages are forwarded to said sterilization step (150) with said one or more portions of fish in the solid form in the frozen state having a core temperature of maximum -5°C. 
Postupak sukladno zahtjevu 1, naznačen time što su zatvoreni paketi poslani na sterilizaciju (150) s jednom ili više porcija ribe u čvrstom obliku u smrznutom stanju s temperaturom jezgre od najviše -5°C.
Process according to anyone of the preceding claims characterized in that it also comprises a step of dosing (125) seasoning liquid, such as for example oil, brine or aromatic dispersions, which salt is possibly added to, and/or other foodstuffs, such as vegetables or other. 
Postupak sukladno bilo kojem od prethodnih zahtjeva naznačen time što također obuhvaća korak doziranja (125) začinske tekućine, kao na primjer ulja, otopine soli ili aromatičnih disperzija, kojima je moguće dodana sol, i/ili druge namirnice, poput povrća ili drugih.
Process according to anyone of the preceding claims characterized in that said at least partially flexible packaging is impermeable to gases, to water, to microorganisms and to light. 
Postupak sukladno bilo kojem od prethodnih zahtjeva naznačen time što je barem djelomično fleksibilno pakiranje nepropusno za plinove, vodu, mikroorganizme i svjetlost.
Process according to claim 4, characterized in that said at least partially flexible packaging is a bag in multilayer material comprising an aluminum layer or other material having analogous barrier properties. 
Postupak sukladno zahtjevu 4, naznačen time što je barem djelomice fleksibilno pakiranje vrećica od višeslojnog materijala koja obuhvaća sloj aluminija ili drugog materijala odgovarajućih obilježja.
Package consisting of one or more portions of fish in the solid form (10), cooked during heat sterilization in an autoclave, with the optional addition only of seasoning liquid and/or other foodstuffs, wherein the package is commercially sterile, characterized in that said one or more portions of fish in the solid form (10) are vacuum contained in an at least partially flexible packaging and have muscle bundles substantially intact and separable from each other. 
Pakiranje koja sadrži jednu ili više porcija ribe u čvrstom obliku (10), kuhane tijekom sterilizacije toplinom u autoklavu, s opcionalnim dodavanjem samo začinske tekućine i/ili drugih namirnica, pri čemu je pakiranje komercijalno sterilno, naznačeno time što su barem jedna ili više porcija ribe u čvrstom obliku (10) sadržane u vakuumu u barem djelomice fleksibilnom pakiranju i sa skupinama mišića koje su u osnovi nedirnute i mogu se međusobno odvojiti.
Package according to claim 6, characterized in that it also comprises a small quantity of cooking liquid (11), limpid and clear, and/or a minimum presence of albumin proteins (14) exudate from said one or more portions of fish in the solid form (10) during cooking, mainly adhered to the surface of said one or more portions of fish in the solid form (10). 
Pakiranje sukladno zahtjevu 6, naznačeno time što također obuhvaća malu količinu tekućine za kuhanje (11), bistre i čiste, i/ili minimalnu količinu proteina albumina (14) eksudata iz jedne ili više porcija ribe u čvrstom obliku (10) tijekom kuhanja, ponajviše uz površinu jedne ili više porcija ribe u čvrstom obliku (10).
Package according to claim 6 or 7, characterized in that said one or more portions of fish in the solid form (10) have soft consistence due to swelling with saline solution. 
Pakiranje sukladno zahtjevu 6 ili 7, naznačeno time što jedna ili više porcija ribe u čvrstom obliku (10) imaju meku konzistenciju zbog upijanja otopine soli.
Package according to anyone of the claims 6 to 8, characterized in that said at least partially flexible packaging is impermeable to gases, to water, to microorganisms and to light. 
Pakiranje sukladno bilo kojem od zahtjeva 6 do 8, naznačeno time što je barem djelomice fleksibilno pakiranje nepropusno za plinove, vodu, mikroorganizme i svjetlost.
Package comprising portions of fish in the solid form (10), cooked during heat sterilization in an autoclave, characterized in that it is made according to the process according to anyone of the claims 1 to 5. 
Pakiranje koje obuhvaća porcije ribe u čvrstom obliku (10), kuhane tijekom sterilizacije toplinom u autoklavu, naznačeno time što je načinjeno sukladno postupku sukladno bilo kojem od zahtjeva 1 do 5.
An orally administrable chewable composition in unit dosage form comprising a set oil-in-water emulsion in which the aqueous phase is gelled and in which the oil phase comprises a fish oil, wherein the weight of said unit dose is 0.25-3g. 
Oralno primjenjiv pripravak za žvakanje u obliku jedinične doze koji sadrži ulje-u-vodi emulziju gdje je vodena faza gelirana i gdje uljna faza obuhvaća riblje ulje, pri čemu je težina te jedinične doze 0.25-3g.
A package as claimed in claim 8 in the form of a blister pack. 
Pakiranje prema zahtjevu 8 u obliku blister pakiranja.
A drug containing the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7 as an active ingredient for use in the therapy or prevention of a disease such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease, Parkinson's disease, Huntington's disease, eating disorder, headache, migraine, pain, gastrointestinal disease, epilepsy, inflammation, immunological disease, endocrine disease or hypertension. 
Lijek koji kao aktivni sastojak sadrži spoj ili njegovu farmaceutski prihvatljivu sol prema bilo kojem od zahtjeva 1 do 7, naznačen time da je za upotrebu za liječenje ili prevenciju bolesti, kao što su poremećaj spavanja, depresija, anksioznost, poremećaj panike, shizofrenija, ovisnost o lijekovima, Alzheimerova bolest, Parkinsonova bolest, Huntingtonova bolest, poremećaj hranjenja, glavobolja, migrena, bol, gastrointestinalna bolest, epilepsija, upala, imunološka bolest, endokrina bolest ili hipertenzija.
Device for injecting at least one chemical substance and/or preparation into trees and/or palmaceae, characterized in that it comprises: 
Naprava za injektiranje najmanje jedne tvari i/ili pripravka u drveće i/ili palme, koja je hermetička i obuhvaća:
The pharmaceutical composition according to one of the previous claims characterized in that the glucopyranosyl-substituted benzene derivative and the DPP IV inhibitor are present in a single dosage form. 
Farmaceutski sastav prema jednom od prethodnih zahtjeva, naznačen time, da su derivat benzena supstituiran glukopiranozilom i DPP IV-inhibitor prisutni u jednostrukom doznom obliku.
The pharmaceutical composition according to one of the previous claims characterized in that the glucopyranosyl-substituted benzene derivative and the DPP IV inhibitor are present each in a separate dosage form. 
Farmaceutski sastav prema jednom od prethodnih zahtjeva, naznačen time, da su derivat benzena supstituiran glukopiranozilom i DPP IV-inhibitor prisutni u odvojenom doznom obliku.
The pharmaceutical composition according to one of the previous claims comprising a DPPIV inhibitor of the embodiment A in a dosage range of 0.5 to 10 mg. 
Farmaceutski sastav prema jednom od prethodnih zahtjeva, naznačen time, da sadrži količinu od 0,5 do 10 mg DPP IV-inhibitora.
The pharmaceutical composition according to claim 12 comprising an amount of 5 to 50 mg of the glucopyranosyl-substituted benzene derivative and an amount of 0.5 to 10 mg of the DPP IV inhibitor. 
Farmaceutski sastav prema zahtjevu 1, 2, 3 ili 4, naznačen time, da sadrži količinu od 5 do 50 mg derivata benzena supstituiranog glukopiranozilom i količinu od 0,5 do 10 mg DPP IV-inhibitora.
The pharmaceutical composition according to one of the previous claims characterized in that it is formulated for oral administration. 
Farmaceutski sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da se farmaceutski sastav formulira za oralnu primjenu u čvrstom obliku.
preventing, slowing, delaying or reversing progression from impaired glucose tolerance, insulin resistance and/or from metabolic syndrome to type 2 diabetes mellitus; or 
prevencija, usporavanje, odgađanje ili ukidanje progresije smanjene tolerancije na glukozu, pogoršane glukoze u krvi natašte, otpornosti na inzulin i/ili od metaboličkog sindroma do dijabetesa melitus tipa 2; ili
The anti-VEGF antibody of claim 30, wherein the progression free survival of the subject is extended by at least about 2.9 months when compared to another subject treated with the chemotherapy alone. 
Protutijelo anti-VEGF za uporabu prema zahtjevu 1, naznačeno time, da režim liječenja učinkovito produžuje preživljavanje pojedinca bez progresije bolesti za najmanje oko 2,9 mjeseci, u usporedbi s nekim drugim pojedincem koji se liječi samo s kemoterapijom.
The anti-VEGF antibody of claim 1, wherein the treatment regimen extends the progression free survival of the subject by at least about 1 month or more when compared to another subject treated with the chemotherapy alone. 
Protutijelo anti-VEGF za uporabu prema zahtjevu 1, naznačeno time, da režim liječenja učinkovito produžuje preživljavanje pojedinca bez progresije bolesti za najmanje oko 2,9 mjeseci, u usporedbi s nekim drugim pojedincem koji se liječi samo s kemoterapijom.
The anti-VEGF antibody of claim 1, wherein the anti-VEGF antibody has a heavy chain variable region comprising the following amino acid sequence: and a light chain variable region comprising the following amino acid sequence: 
Protutijelo anti-VEGF za uporabu prema zahtjevu 1, naznačeno time, da protutijelo anti-VEGF ima varijabilno područje jakog lanca, koje sadrži sljedeće aminokiselinske sekvence: [image] i varijabilno područje slabog lanca, koje sadrži sljedeće aminokiselinske sekvence:
The apparatus of claim 1, wherein the intra prediction mode is coded using an upper intra prediction mode and a left intra prediction mode, and when the upper intra prediction mode or the left intra prediction mode is unavailable, the upper intra prediction mode or the left intra prediction mode is set to a DC mode. 
Uređaj prema zahtjevu 1, naznačen time da je način unutarokvirnog predviđanja kodiran korištenjem gornjeg načina unutarokvirnog predviđanja i lijevim načinom unutarokvirnog predviđanja, i kada je gornji način unutarokvirnog predviđanja ili lijevi način unutarokvirnog predviđanja nedostupan, gornji način unutarokvirnog predviđanja ili lijevi način unutarokvirnog predviđanja je namješten na DC način.
Binding element according to claim 1, characterised in that the first cover sheet (3) has a gloss surface. 
Element za povezivanje sukladno zahtjevu 1, naznačen time što prvi list (3) ima sjajnu površinu.
Binding element according to any one of the previous claims, characterised in that the second cover sheet (4) has a matt surface. 
Element za povezivanje sukladno bilo kojem od prethodnih zahtjeva, naznačen time što drugi pokrovni list (4) ima mat površinu.
Binding element according to claim 4 or 5, characterised in that the arms (6) have a length (L) of 9 mm or more. 
Element za povezivanje sukladno zahtjevu 4 ili 5, naznačen time što krakovi (6) imaju duljinu (L) od 9 mm ili više.
Binding element according to claim 6, characterised in that the arms (6) have a length (L) of 9.5 to 11.5 mm. 
Element za povezivanje sukladno zahtjevu 6, naznačen time što krakovi (6) imaju duljinu (L) od 9.5 do 11.5 mm.
Binding element according to claim 9, characterised in that the spine (2) is such that it is plastically deformable to enable the adjustment of the said distance by manually pushing the arms (5) towards one another without tools. 
Element za povezivanje sukladno zahtjevu 9, naznačen time što je greben (2) takav da se može plastično deformirati kako bi se omogućila prilagodba udaljenosti ručnim guranjem krakova (5) jednog prema drugome bez alata.
An ophthalmic surgical device (1) according to claim 2, characterized in that the notch (6) is located close to the rounded tip (7). 
Oftamološki kirurški uređaj (1) prema zahtjevu 2, naznačen time što se urez (6) nalazi blizu zaobljenog vrha (7).
is selected from hydrogen and fluoro. 
je odabran od vodika i fluora.
is selected from chloro, fluoro and methyl; 
je odabran od klora, fluora i metila;
is selected from hydrogen, chloro and fluoro; 
je odabran od vodika, klora i fluora;
is selected from fluoro and chloro; and 
je odabran od fluora i klora; i
is selected from ethyl and isopropyl. 
je odabran od etila i izopropila.
The pharmaceutical composition of claim 9, wherein the additional therapeutic agent is selected from an anticancer compound, an analgesic, an antiemetic, an antidepressant, and an anti-inflammatory agent. 
Farmaceutski sastav prema zahtjevu 9, naznačen time, da je dodatno terapeutsko sredstvo odabrano od antikanceroznog spoja, analgetika, antiemetika, antidepresiva i protuupalnog sredstva.
The compound for use in a method of treatment according to claim 8 or the use of claim 9, wherein the cancer to be treated is selected from the group consisting of lung carcinoma, pancreatic carcinoma, bladder carcinoma, colon carcinoma, myeloid disorders, prostate cancer, thyroid cancer, melanoma, adenomas and carcinomas of the ovary, eye, liver, biliary tract, and nervous system. 
Spoj za uporabu u postupku liječenja prema zahtjevu 11 ili uporaba prema zahtjevu 12, naznačen/a time, da je rak koji se treba liječiti odabran iz skupine koju čine: karcinom pluća, karcinnom pankreasa, karcinom mjehura, karcinom debelog crijeva, mijeloidni poremećaji, rak prostate, rak štitnjače, melanom, adenomi i karcinomi jajnika, oka, jetre, žučnog trakta i nervnog sustava.
The compound for use in a method of treatment according to claim 11 or the use of claim 12, the method further comprising administering to the subject an additional therapeutic agent, optionally wherein the additional therapeutic agent is administered to the subject concurrently with the compound. 
Spoj za uporabu u postupku liječenja prema zahtjevu 11 ili uporaba prema zahtjevu 12, naznačen/a time, da postupak nadalje obuhvaća primjenu dodatnog terapeutskog sredstva na pojedincu, pri čemu se dodatno terapeutsko sredstvo na pojedincu opcijski primjenjuje istovremeno sa spojem.
The compound for use in a method of treatment according to claim 11 or the use of claim 12, the method further comprising administering to the subject an additional therapeutic agent, optionally wherein the additional therapeutic agent is administered to the subject sequentially with the compound. 
Spoj za uporabu u postupku liječenja prema zahtjevu 11 ili uporaba prema zahtjevu 12, naznačen/a time, da postupak nadalje obuhvaća primjenu dodatnog terapeutskog sredstva na pojedincu, pri čemu se dodatno terapeutsko sredstvo na pojedincu opcijski primjenjuje uzastopno sa spojem.
the additional therapeutic agent comprises an anticancer drug, a pain medication, an antiemetic, an antidepressant or an anti-inflammatory agent; or 
dodatno terapeutsko sredstvo obuhvaća antikanceroznu ljekovitu tvar, lijek protiv bolova, antiemetik, antidepresiv ili protuupalno sredstvo; ili
The compound for use in a method of treatment or the use according to claim 18 wherein the melanoma is metastatic melanoma or the colorectal cancer is colon carcinoma 
Spoj za uporabu u postupku liječenja ili uporaba prema zahtjevu 18, naznačen/a time, da melanom je metastazirani melanom ili kolorektalni rak je karcinom debelog crijeva.
A laminated acoustic building panel as claimed in claim 1 or claim 2, in which the adhesive has a dynamic Young's modulus (at 20°C) of 0.1 to 0.5 MPa at 100 Hz and/or 0.5 MPa to 100 MPa at 1000 Hz and a loss factor of at least 50% (n > 0.5). 
Laminirana akustična građevinska ploča prema zahtjevu 1 ili zahtjevu 2, naznačena time da ljepilo ima dinamički Youngov modul (kod 20°C) od 0.1 do 0.5 MPa kod 100 Hz i/ili 0.5 MPa do 100 MPa kod 1000 Hz i faktor gubitka od barem 50% (n > 0.5).
A composition comprising an effective amount of an avermectin compound in combination with an effective amount of a non-steroidal anti-inflammatory drug (NSAID), or suitable pharmaceutically acceptable salts thereof, for use in the inhibition of tumor growth and treatment of cancer. 
Pripravak koji sadrži učinkovitu količinu spoja avermektina u kombinaciji s učinkovitom količinom nesteroidnog protuupalnog lijeka (NSAID), ili njihovim pogodnim farmaceutski prihvatljivim solima, naznačen time da je za uporabu za inhibiciju rasta tumora i liječenje raka.
The composition for use in the inhibition of tumor growth and treatment of cancer according to anyone of claims 1-3, wherein the non-steroidal anti-inflammatory drug (NSAID) is selected from the group consisting of salicylates, propionic acids, acetic acids, enolic acids, fenamic acid, selective COX-2 inhibitors and sulphonanilides. 
Pripravak za primjenu za inhibiciju rasta tumora i liječenje raka prema bilo kojem od zahtjeva 1-3, naznačen time da je nesteroidni protuupalni lijek (NSAID) odabran iz skupine koju čine salicilati, propionske kiseline, octene kiseline, enolne kiseline, fenaminska kiselina, selektivni inhibitori COX-2 i sulfonanilidi.
The composition for use in the inhibition of tumor growth and treatment of cancer according to claim 4, wherein the propionic acid compound is selected from the group consisting of ibuprofen, naproxen, fenoprofen, ketoprofen, flurbiprofen, oxaprozin and loxoprofen. 
Pripravak za primjenu za inhibiciju rasta tumora i liječenje raka prema zahtjevu 4, naznačen time da je spoj propionske kiseline odabran iz skupine koju čine ibuprofen, naproksen, fenoprofen, ketoprofen, flurbiprofen, oksaprozin i loksoprofen.
The composition for use in the inhibition of tumor growth and treatment of cancer according to claim 5, wherein the propionic acid compound is ibuprofen. 
Pripravak za primjenu za inhibiciju rasta tumora i liječenje raka prema zahtjevu 5, naznačen time da spoj propionske kiseline je ibuprofen.
The composition for use in the inhibition of tumor growth and treatment of cancer according to claim 4, wherein the acetic acid compound is diclofenac. 
Pripravak za primjenu za inhibiciju rasta tumora i liječenje raka prema zahtjevu 4, naznačen time da spoj octene kiseline je diklofenak.
The composition for use in the inhibition of tumor growth and treatment of cancer according to claims 1, comprising an effective amount of ivermectin and an effective amount of a NSAID. 
Pripravak za primjenu za inhibiciju rasta tumora i liječenje raka prema zahtjevu 1, naznačen time da sadrži učinkovitu količinu ivermektina i učinkovitu količinu NSAID.
The composition for use in the inhibition of tumor growth and treatment of cancer according to claim 8, comprising an effective amount of ivermectin and an effective amount of ibuprofen. 
Pripravak za primjenu za inhibiciju rasta tumora i liječenje raka prema zahtjevu 8, naznačen time da sadrži učinkovitu količinu ivermektina i učinkovitu količinu ibuprofena.
The composition for use in the inhibition of tumor growth and treatment of cancer according to claim 8, comprising an effective amount of ivermectin and an effective amount of diclofenac. 
Pripravak za primjenu za inhibiciju rasta tumora i liječenje raka prema zahtjevu 8, naznačen time da sadrži učinkovitu količinu ivermektina i učinkovitu količinu diklofenaka.
The composition for use in the inhibition of tumor growth and treatment of cancer according to anyone of claims 1-10, wherein the cancer is of the group consisting of urothelial cancer, colorectal cancer, prostate cancer and breast cancer. 
Pripravak za primjenu za inhibiciju rasta tumora i liječenje raka prema bilo kojem od zahtjeva 1-10, naznačen time da rak je iz skupine koju čine rak mokraćnog mjehura, rak debelog crijeva, rak prostate i rak dojke.
The composition for use in the inhibition of tumor growth and treatment of cancer according to claim 11, wherein the cancer is colorectal cancer. 
Pripravak za primjenu za inhibiciju rasta tumora i liječenje raka prema zahtjevu 11, naznačen time da rak je rak debelog crijeva.
A composition for use in improving at least one member selected from the group consisting of a social domain and a communication domain in a human having autism, wherein the composition includes a therapeutically effective amount at least one gamma-aminobutyric acid agonist. 
Pripravak namijenjen upotrebi u poboljšavanju najmanje jednog člana kojeg se bira iz skupine koju čine socijalne vještine i komunikacijske vještine kod osobe s autizmom, naznačen time što pripravak sadrži terapijski djelotvornu količinu najmanje jednog agonista γ-aminomaslačne kiseline.